Qube Research & Technologies LTD Arcus Biosciences, Inc. Transaction History

Qube Research & Technologies LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$22.75 - $35.77 $533,100 - $838,198	-23,433 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$26.16 - $41.39 $332,912 - $526,729	12,726 Added 118.86%	23,433 $658,000
Q4 2020 Feb 16, 2021	SELL	$17.0 - $32.36 $7,157 - $13,623	-421 Reduced 3.78%	10,707 $278,000
Q3 2020 Nov 12, 2020	SELL	$17.14 - $25.47 $340,554 - $506,063	-19,869 Reduced 64.1%	11,128 $191,000
Q2 2020 Aug 14, 2020	BUY	$13.97 - $36.56 $433,028 - $1.13 Million	30,997 New	30,997 $767,000

186

49.2M

204K

149K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.